Edition:
United Kingdom

Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

169.03USD
3:17pm BST
Change (% chg)

$-2.36 (-1.38%)
Prev Close
$171.39
Open
$170.69
Day's High
$171.00
Day's Low
$168.91
Volume
245,778
Avg. Vol
3,116,942
52-wk High
$184.21
52-wk Low
$133.64

AMGN.O

Chart for AMGN.O

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN... (more)

Overall

Beta: 1.36
Market Cap(Mil.): $125,059.00
Shares Outstanding(Mil.): 729.67
Dividend: 1.15
Yield (%): 2.68

Financials

  AMGN.O Industry Sector
P/E (TTM): 15.59 58.88 32.14
EPS (TTM): 11.00 -- --
ROI: 11.98 -0.12 13.99
ROE: 26.43 2.88 15.33

BRIEF-Soros Fund Management LLC dissolves share stake in Alphabet, Amgen, American Airlines ‍​

* Soros Fund Management LLC dissolves share stake in Alphabet Inc class A shares ‍​

14 Aug 2017

BRIEF-Temasek Holdings takes stake in JPMorgan, Biogen, Celgene

* Temasek Holdings (Private) Ltd takes share stake in JPMorgan Chase & Co of 264,337 shares

14 Aug 2017

Fitch Downgrades AstraZeneca to 'A-'; Outlook Negative

(The following statement was released by the rating agency) LONDON, August 01 (Fitch) Fitch Ratings has downgraded UK-based pharmaceutical company AstraZeneca PLC's (AZ) Long-Term Issuer Default Rating (IDR) and senior unsecured rating to 'A-' from 'A'. The Outlook is Negative. The downgrade reflects AstraZeneca's increasing business risk as the pharmaceutical group transitions into next-generation therapies. The company's recent mixed late-stage pipeline developments in oncology - an increasing

01 Aug 2017

UPDATE 1-Express Scripts to cover Mylan's EpiPen, exclude rivals

NEW YORK, July 31 Pharmacy benefit manager Express Scripts Holding Co said on Monday it would favor drugmaker Mylan Inc's versions of the EpiPen lifesaving allergy treatment over the allergy auto-injectors of other companies.

31 Jul 2017

BRIEF-Amgen and Allergan submit biosimilar Biologics License application for ABP 980 to U.S. FDA

* Amgen and Allergan submit biosimilar Biologics License Application for ABP 980 to US Food and Drug Administration

31 Jul 2017

BRIEF-Amgen submits supplemental biologics license application for Prolia in glucocorticoid-induced osteoporosis

* Amgen submits supplemental biologics license application for Prolia® (denosumab) in glucocorticoid-induced osteoporosis

31 Jul 2017

BRIEF-Amgen sets quarterly dividend of $1.15/shr

* Sets quarterly dividend of $1.15per share Source text for Eikon: Further company coverage:

28 Jul 2017

Amgen gets fast FDA review for adding heart benefits to cholesterol drug label

Amgen Inc said on Thursday the U.S. Food and Drug Administration granted priority review to the company's request to add important heart safety data to the label of its expensive injectable cholesterol drug Repatha.

27 Jul 2017

Amgen gets fast U.S. FDA review for adding heart benefits to cholesterol drug label

July 27 Amgen Inc said on Thursday the U.S. Food and Drug Administration granted priority review to the company's request to add important heart safety data to the label of its expensive injectable cholesterol drug Repatha.

27 Jul 2017

BRIEF-FDA grants priority review for Amgen's supplemental biologics license application for Repatha

* FDA grants priority review for Amgen's supplemental biologics license application for Repatha® (evolocumab) to include data on reducing risk of cardiovascular events

27 Jul 2017

Earnings vs. Estimates